Acutus Medical

Acutus Medical, Inc. engages in the development of medical devices and electrophy equipment. It creates electrophysiological mapping systems for the treatment of cardiac arrhythmias, such as atrial fibrillation, and ventricular tachycardia. The company was founded by Randell L. Werneth and Christoph Scharf in 2011 and is headquartered in Carlsbad, CA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CARLSBAD, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Acutus Medical to Announce Fourth Quarter and Full Year 2022 Financial Results

The AcQBlate Force Sensing Ablation Catheter and System demonstrated 94% acute success with no serious adverse events and significantly less ablation time The AcQBlate Force Sensing Ablation Catheter and System demonstrated 94% acute success with no serious adverse events and significantly less ablation time

Late-Breaking ACQFORCE FLUTTER Trial Meets Primary Endpoint for Safety and Efficacy with the First Gold-Tipped Contact Force Sensing Ablation Catheter

CARLSBAD, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the fourth quarter and full year 2022. The Company also announced the appointment of Takeo Mukai as Senior Vice President & Chief Financial Officer.

Acutus Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Results and Appointment of Chief Financial Officer

CARLSBAD, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the acceptance of the AcQForce Flutter abstract titled “AcQForce Flutter Trial Clinical Results: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter” for presentation during the Late-Breaking Clinical Trials and First Report Investigations session at the AF Symposium in Boston. This abstract – including full study results - will be presented on Friday, February 3, 2023.

Acutus Medical Announces Acceptance of the AcQForce Flutter Abstract for Presentation during the Late-Breaking Clinical Trials and First Report Investigations sessions at the 2023 AF Symposium

CARLSBAD, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced that the Company has achieved the second milestone under the asset purchase agreement with Medtronic of its left-heart access portfolio with the submission for CE Mark of this portfolio under European Union (EU) Medical Device Regulations (MDR). This milestone triggers a $17 million earnout payment from Medtronic to Acutus.

Acutus Medical Achieves EU MDR Submission Milestone in Sale of Left-Heart Access Portfolio to Medtronic

Software improvements further leverage the system's unique ultrasound capabilities for non-contact anatomy reconstruction Software improvements further leverage the system's unique ultrasound capabilities for non-contact anatomy reconstruction

Acutus Medical Announces Full Market Release of next generation software platform AcQMap 8.5

The flagship 3D mapping catheter from Acutus Medical has been certified under the new European Medical Device Regulations The flagship 3D mapping catheter from Acutus Medical has been certified under the new European Medical Device Regulations

Acutus Medical Obtains MDR CE Mark of the AcQMap 3D Imaging and Mapping Catheter

Acutus Medical, Inc. (NASDAQ:AFIB ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Caroline Corner - Investor Relations David Roman - President & Chief Executive Officer Takeo Mukai - Vice President, Finance & Accounting, Interim Chief Financial Officer Conference Call Participants Marie Thibault - BTIG John Young - Canaccord Genuity Margaret Kaczor - William Blair Philip Coover - Goldman Sachs Javier Fonseca - Spartan Capital Operator Good day, and thank you for standing by. Welcome to the Acutus Medical Third Quarter 2022 Earnings Call.

Acutus Medical, Inc. (AFIB) Q3 2022 Earnings Call Transcript

Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of 13.25% and 3.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Acutus Medical, Inc. (AFIB) Reports Q3 Loss, Tops Revenue Estimates

CARLSBAD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the third quarter of 2022.

Acutus Medical Reports Third Quarter 2022 Financial Results

CARLSBAD, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2022 financial results on Thursday, November 10, 2022. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Acutus Medical to Announce Third Quarter 2022 Financial Results

CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced submission of pivotal clinical data from the AcQForce Flutter trial designed to gain marketing approval from the U.S. Food & Drug Administration (FDA) for the AcQBlate Force Sensing Ablation Catheter and System (AcQBlate FORCE). Catheter ablation procedures to treat right atrial flutter account for approximately 30% of ablations in the US and are expected to reach 200,000 by 20251.

Acutus Medical Announces Submission of Premarket Approval Application for AcQBlate Force Sensing Ablation Catheter & System

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces that it has been appointed Lead Counsel in the securities class action against Acutus Medical, Inc. (“Acutus” or the “Company”) (NASDAQ: AFIB) and certain executive officers of the Company, currently pending in the United States District Court for the Southern District of California. Investors that purchased Acutus common stock between May 13, 2021 and November 11, 2021 are encouraged to contact Charles H. Linehan,

SHAREHOLDER UPDATE: Glancy Prongay & Murray LLP Appointed Lead Counsel in Securities Class Action Against Acutus Medical, Inc.

Acutus Medical, Inc. (NASDAQ:AFIB ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Caroline Corner - Investor Relations David Roman - Chief Executive Officer & Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Allen Gong - JPMorgan Marie Thibault - BTIG Javier Fonseca - Spartan Capital John Young - Canaccord Operator Good day and welcome to the Acutus Medical Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Acutus Medical, Inc. (AFIB) CEO David Roman on Q2 2022 Results - Earnings Call Transcript

CARLSBAD, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its second quarter 2022 financial results on Thursday, August 11, 2022. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Acutus Medical to Announce Second Quarter 2022 Financial Results

Approval ushers in a new era of arrhythmia management in Japan through revolutionary non-contact imaging and diagnosis technology Approval ushers in a new era of arrhythmia management in Japan through revolutionary non-contact imaging and diagnosis technology

Acutus Medical Announces Approval of its AcQMap System and AcQMap 3D Imaging and Mapping Catheter in Japan

CARLSBAD, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced that David Roman has been appointed President and Chief Executive Officer, and member of the Board of Directors, effective immediately. The Company also announced preliminary second quarter revenue results.

Acutus Medical Announces CEO Appointment and Preliminary Second Quarter Revenue Results

CARLSBAD, Calif., July 01, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the completion of the first of two closings for its previously disclosed sale of the Company's left-heart access portfolio to Medtronic, Inc. (“Medtronic”) and entry into a new longer-term credit facility with Deerfield Management Company (“Deerfield”) to refinance its existing debt. The Company expects these transactions to fund its long-term growth objectives.

Acutus Medical Completes First Closing of Transaction with Medtronic and Debt Refinancing to Fund Strategic Growth Priorities

AFIB stock traders are celebrating as the FDA clears its arrhythmia management product for commercialization. The post Why Is Acutus Medical (AFIB) Stock Up 100% Today?

Why Is Acutus Medical (AFIB) Stock Up 100% Today?

Agile Therapeutics

Cybin

Evofem Biosciences Inc

Hillstream Biopharma

Penny stocks to watch with news The post Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving

Acutus Medical Inc (NASDAQ: AFIB) has launched an expanded suite of left-heart access products, including the AcQCross Qx system for use with the TruSeal and FXD delivery system for the Watchman LAAC Device. AcQCross is a transseptal system engineered with an integrated needle and.

Why Acutus Medical Shares Are Rallying Today?

Innovative Transseptal Access System Is First and Only to Feature Integrated Dilator and Needle to Reduce Exchanges Innovative Transseptal Access System Is First and Only to Feature Integrated Dilator and Needle to Reduce Exchanges

Acutus Medical Announces FDA Clearance, Commercial Launch of AcQCross™ Line Extension Compatible with Watchman™ Delivery System

CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced successful completion of patient enrollment in the company's AcQForce™ Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at 21 sites globally.

Acutus Medical completes enrollment in IDE trial with its AcQBlate® FORCE Sensing Ablation System

Acutus Medical, Inc. (NASDAQ:AFIB ) Q2 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Caroline Corner - IR Scott Huennekens - Chairman David Roman - Interim CEO and CFO Conference Call Participants Brandon Vazquez - William Blair Marie Thibault - BTIG Bill Plovanic - Canaccord Genuity Javier Fonseca - Spartan Capital Operator Thank you for standing by and welcome to the Acutus Medical, Inc. First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Acutus Medical, Inc. (AFIB) CEO Vince Burgess on Q2 2022 Results - Earnings Call Transcript l: ZIP

Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of -1.01% and 29.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Acutus Medical Stock (AFIB)